Citation Impact
Citing Papers
Removing T-cell epitopes with computational protein design
2014 StandoutNobel
Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial
2016
CD8+CD205+ Splenic Dendritic Cells Are Specialized to Induce Foxp3+ Regulatory T Cells
2008 StandoutNobel
Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
2014
Regulatory T-cells in autoimmune diseases: Challenges, controversies and—yet—unanswered questions
2014
Hallmarks of Cancer: The Next Generation
2011 Standout
Re-establishing immunological self-tolerance in autoimmune disease
2012 StandoutNobel
Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?
2012
The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins
2008 StandoutNature
Oncology Meets Immunology: The Cancer-Immunity Cycle
2013 Standout
Hepatocellular carcinoma
2016 Standout
Hepatocellular carcinoma
2018 Standout
mRNA-based therapeutics — developing a new class of drugs
2014 StandoutNobel
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
2011 StandoutNature
Regulatory T Cells in Cancer
2010
Regulatory T Cells and Immune Tolerance
2008 StandoutNobel
Immune regulation in tumor-bearing hosts
2006
TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials
2016
Chemoimmunotherapy: reengineering tumor immunity
2013
Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma
2016
CCR4 as a novel molecular target for immunotherapy of cancer
2006
Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib
2014
Development of TLR9 agonists for cancer therapy
2007
Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival
2019
Transforming growth factor-β induces development of the TH17 lineage
2006 StandoutNature
Apoptosis in cancer: from pathogenesis to treatment
2011 Standout
Interleukin-17 and Type 17 Helper T Cells
2009 Standout
Liver cancer: Approaching a personalized care
2015
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Selectively functionalized cyclodextrins and their metal complexes
2009
TGFβ in Cancer
2008 Standout
Cancer immunotherapy comes of age
2011 StandoutNature
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
The blockade of immune checkpoints in cancer immunotherapy
2012 Standout
FOXP3+ regulatory T cells in the human immune system
2010 StandoutNobel
Regulatory T cells in cancer immunotherapy
2014 StandoutNobel
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
2021
Targeting Immunosupportive Cancer Therapies: Accentuate the Positive, Eliminate the Negative
2007 StandoutNobel
Development of an anti‐IL‐17A auto‐vaccine that prevents experimental auto‐immune encephalomyelitis
2006
Molecular therapies and precision medicine for hepatocellular carcinoma
2018
Indoleamine 2,3-dioxygenase and tumor-induced tolerance
2007
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
2011 StandoutNobel
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
2006
Interleukin‐10‐secreting type 1 regulatory T cells in rodents and humans
2006
Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA
2006
Microenvironmental regulation of tumor progression and metastasis
2013 Standout
Treatment of Hepatocellular Carcinoma
2016
The prognostic landscape of genes and infiltrating immune cells across human cancers
2015 Standout
Advances in targeted therapies for hepatocellular carcinoma in the genomic era
2015
Sorafenib for the Treatment of Advanced Hepatocellular Cancer – a UK Audit
2016
Hepatocellular carcinoma
2022 Standout
Human FOXP3+ Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer
2019 StandoutNobel
Hepatocellular carcinoma: clinical frontiers and perspectives
2014
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
2023 StandoutNobel
Hepatocellular Carcinoma
2019 Standout
AASLD guidelines for the treatment of hepatocellular carcinoma
2017 Standout
Attenuation of CD8+ T-Cell Function by CD4+CD25+ Regulatory T Cells in B-Cell Non-Hodgkin's Lymphoma
2006
High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma
2006
CD4+CD25−LAG3+regulatory T cells controlled by the transcription factor Egr-2
2009 StandoutNobel
Regulatory T Cells and Human Disease
2020 StandoutNobel
Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients
2006 StandoutNobel
Unc93B1 biases Toll-like receptor responses to nucleic acid in dendritic cells toward DNA- but against RNA-sensing
2009 StandoutNobel
Regulatory T cells in cancer
2006
Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design
2014
The AP1-dependent secretion of galectin-1 by Reed–Sternberg cells fosters immune privilege in classical Hodgkin lymphoma
2007 Standout
Supramolecular Chirality in Self-Assembled Systems
2015 Standout
T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production
2012
Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma
2008 StandoutNobel
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
2017 Standout
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model
2012 StandoutNobel
Cyclophosphamide-Induced Type-1 Diabetes in the NOD Mouse Is Associated with a Reduction of CD4+CD25+Foxp3+ Regulatory T Cells
2006
Specific Recruitment of CC Chemokine Receptor 4–Positive Regulatory T Cells in Hodgkin Lymphoma Fosters Immune Privilege
2006
Responses to Human CD40 Ligand/Human Interleukin-2 Autologous Cell Vaccine in Patients with B-Cell Chronic Lymphocytic Leukemia
2005
Chimeric Antigen Receptor Therapy
2018 Standout
Emerging Challenges in Regulatory T Cell Function and Biology
2007 StandoutScienceNobel
Dysfunctional T regulatory cells in multiple myeloma
2005
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+regulatory T cells, evoking antitumor immune responses in humans
2013 StandoutNobel
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
TRANSFORMING GROWTH FACTOR-β REGULATION OF IMMUNE RESPONSES
2005 Standout
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
2014
Regulatory roles of IL-10–producing human follicular T cells
2019 StandoutNobel
Quantification of Regulatory T Cells Enables the Identification of High-Risk Breast Cancer Patients and Those at Risk of Late Relapse
2006
In vivo peripheral expansion of naive CD4+CD25highFoxP3+ regulatory T cells in patients with multiple myeloma
2006
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
2013 StandoutNobel
Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma
2020
A β-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy
2005
Works of Markus Jensen being referenced
Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia
2007
Breaking of B cell tolerance toward a highly conserved self protein.
1996
Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine
2005
SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma
2014